The use of any investigational medication or device in the  days prior to screening and throughout the study is prohibited.
Patients who need to continue treatment with any prohibited medications
Patients who have not completed the appropriate washout period for the prohibited medications
For Cohort E only: prior treatment with fulvestrant is prohibited
Current use of a prohibited medication
Use of any prohibited medication within the timeframes
Concurrent treatment with a prohibited medication.
Requirement for concomitant therapy or food that is prohibited during the study
Chronic use of moderate or strong CYPA modulators (inhibitor or inducer) or any other prohibited medications. A washout period of  days is required prior to venetoclax dosing if a prohibited medication is discontinued.
Currently taking a prohibited concomitant medication, other than a premedication, that are/is:
Patients who are on any prohibited medication; a wash-out period of minimum  weeks prior to registration is mandatory for the patient to be eligible for the study
Current use of a prohibited medication as described
A list of prohibited medications on study are listed
Current use, or up to  days prior use, of certain prohibited medication or requires any of these medications during treatment phase.
Requiring treatment with any of the prohibited concomitant medications listed that cannot be stopped for the duration of trial participation
Current use of a prohibited medication while on dabrafenib/trametinib
Use of other prohibited medications within  days prior to cycle  day  on study (Arms B and C only) (see Appendix  for list of prohibited medications)
Is currently taking any prohibited medication(s).
Currently receiving treatment with any other agent listed on the prohibited medication list
Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation
Use of a prohibited concomitant medication that cannot be safely discontinued or substituted.
Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs. This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who is expected to require a QT prolonging medication while on trial should not be enrolled.
Unable to discontinue the use of prohibited medications
Subjects taking prohibited medications with the exception of systemic corticosteroids. A washout period of at least  elimination half-lives (or as clinically indicated) should occur for prohibited medications prior to the start of treatment
Receiving or anticipated to receive medications prohibited in the protocol.
Patients receiving prohibited medications; prohibited medications or those to be used with caution (i.e., ketoconazole, itraconazole, ritonavir, macrolide antibiotics, erythromycin phenytoin, phenobarbital, carbamazapine, and valproic acid)
Current or previous use of a prohibited medication as listed in the protocol;
Current use of any of the prohibited drugs
Patients receiving prohibited concomitant medications that cannot be discontinued or replaced by safe alternative medication at least  half-lives of the concomitant medication or  days, whichever is longer, prior to the start of pazopanib treatment.
Subjects taking prohibited medications; a washout period of prohibited medications for a period of at least two weeks or as clinically indicated should occur prior to the start of treatment
Current use of a prohibited medication
Use of prohibited medications that cannot be changed to an alternative therapy
Use of any prohibited concomitant medications within the prior  weeks
Any prohibited prior or concomitant therapy
Use of any prohibited concomitant medications within  days of registration
Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation
Current use of a prohibited medication
Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug
Treatment with prohibited medications
Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK.
Be taking or require the use of prohibited medications
Received any treatments prohibited in this trial
Co-administration of aprepitant and fosaprepitant during this study is prohibited
Is currently taking any prohibited medication(s)
Use of prohibited drugs
Current use of a prohibited medication or requires any of these medications during treatment with study drug
Prohibited treatments and or therapies
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
Any other prohibited or restricted medication as described in the study protocol.
Current use of prohibited medications
Any prohibited concomitant medication as per protocol within  days of Screening
Subject is receiving prohibited medications or treatments that cannot be discontinued/replaced by an alternative therapy
Current use of a prohibited medication
Treatment with prohibited medications less than or equal to  days prior to\n             treatment with rociletinib
Current or planned use of prohibited meds
Patients who are taking any of the prohibited medications; if a patient is willing to discontinue such a medication in order to participate in the study, then there must be an appropriate washout period, based on the half-life of the particular drug, prior to the start of the study treatment
On a prohibited medication which cannot be stopped during the duration of HCV treatment
Current use of a prohibited medication
Is currently taking any prohibited medication(s)
Subject is currently receiving treatment with any agent listed on the prohibited medication list
Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs (details will be available in the protocol). This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who may require a QT prolonging medication while on trial should not be enrolled.
Is currently taking any prohibited medication(s)
Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug.
Prohibited Treatments and/or Restricted Therapies
Patients receiving prohibited concomitant medications at the start of the study
Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK.
Any prohibited medication
Patients receiving certain medications and/or substances that are prohibited within stated wash-out periods
Current use of prohibited medication(s) or requirement for prohibited medications during study as per the study protocol. Use of anticoagulants such as warfarin is permitted; however, international normalization ratio (INR) must be monitored according to local institutional practice.
Current use of any of the drugs (prohibited concomitant medications)
Use of any prohibited concomitant medications within  days prior to cycle , day 
Current use of a prohibited medication
Use of other prohibited medications within  half-lives or  days prior to the first dose of study drugs or requires any of these medications while receiving medication on this study
Current use of a prohibited medication while on dabrafenib
Willing and able to discontinue prohibited concomitant medications and/or treatments for CTCL during the study
Current use of a prohibited medication or requires any of these medications during treatment with lapatinib prior to study entry
Any prohibited concomitant medications for therapy with afatinib or gefitinib
Is on any specifically prohibited medication or requires any of these medications during treatment with pazopanib
Current use of a prohibited medication or expected to require any of these medications during treatment with study treatment.
Currently receiving treatment with any prohibited medication(s)
Use of prohibited medications:
Treatment with prohibited medications less than or equal to  days prior to first day of study treatment
Current use of a prohibited medication or expected to require any of these medications during treatment with the investigational drug
A condition that is expected to require concomitant use of any medication listed as prohibited while on study.
Use of any prohibited concomitant medications (washout period of  week)
Current use of a prohibited medication per protocol or expected to require any of these medications during treatment with study drug.
The following medications are prohibited during the study:\r\n* Immunosuppressive agents (except to treat a drug-related adverse event) are prohibited during the study\r\n* Systemic corticosteroids >  mg daily prednisone equivalent\r\n* Any concurrent chemotherapy, hormonal therapy, immunotherapy, or investigational agents for treatment of cancer are prohibited during the study
Has, within  weeks prior to Day , received a medication prohibited based on CYPA interaction
Requires administration of a prohibited medication or treatment;
Requiring treatment with any of the prohibited concomitant medications
Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment:
Any prohibited medication(s) or herbal preparation as described in the protocol or requires any of these medications during the study.
Current use of a prohibited medication as described in the protocol.
Current use of a prohibited medication
Subjects who are not currently taking prohibited medication
Any prohibited medication(s) as described in protocol
Any prohibited medication
Any prohibited medication(s), currently used or expected to be required.
Current use of a prohibited medication or herbal preparation or requires any of these medications during the study.
Prohibited Treatments and/or Therapies
The systemic use of the following therapies are prohibited within  days of first dose of study medication, or longer where indicated:
Must not be on any prohibited medications.
Use of any prohibited medications within  days of the first dose of study medication
Current use of a prohibited medication or requires any of these medications during treatment with study drug.
Currently receiving treatment with any medications listed on the prohibited medication listed in the protocol
Patients who are on any prohibited medication; they have to be have a wash-out period of at least  weeks prior to registration, in order to be eligible for the study
Patients taking prohibited medication listed in the protocol
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
At screening has received any listed prohibited prior and concomitant treatments and procedures
Is receiving any prohibited drugs
Patients who need to continue treatment with any prohibited medications
Patients who have not completed the appropriate washout period for the prohibited medications
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not a prohibited medication
Current use of a prohibited medication or requires any of these medications during treatment with GSK